BioMarin Q3 Revenue Tops $1B but FY26 EPS Guidance Cut to $2.80-$3.10
BMRN is trading near its 52-week low of $49.259 (11% above the low).
Summary
BioMarin's Q3 revenue rose 32% to $1,025 million, but a $123 million GAAP loss and a cut in full-year Non-GAAP EPS guidance to $2.80-$3.10 from $4.90-$5.10 reset the earnings outlook.
Key Events · Earnings and Guidance · BMRN
-
Q3 Revenue Tops $1 Billion
Total revenues were $1,025 million, up 32% Y/Y, driven by 44% growth in Metabolic Conditions including newly acquired GALAFOLD ($152M) and POMBILITI + OPFOLDA ($49M).
-
GAAP Loss Widens on Deal Costs
GAAP net loss was $123 million (-$0.63 diluted EPS) versus a $31 million loss a year ago, reflecting Amicus intangible amortization, interest expense and a $288 million acquired IPR&D charge; Non-GAAP income was $45 million ($0.23 per share).
-
Full-Year EPS Guidance Cut Sharply
Non-GAAP diluted EPS guidance fell to $2.80-$3.10 from $4.90-$5.10, with about $1.55 per share from the Alesta acquisition and $0.32 from the BMN 450 license; total revenue guidance was trimmed to $3,800-$3,900 million.
-
VOXZOGO Order Timing Trims Outlook
VOXZOGO revenue guidance was lowered to $975-$1,025 million from $1,000-$1,050 million because a large international order slipped from Q3 into Q4.
Analysis · BMRN · Life Sciences
Revenue crossed $1 billion for the first time, rising 32% to $1,025 million, yet the quarter still produced a $123 million GAAP net loss (-$0.63 per share) as Amicus amortization, interest expense and a $288 million acquired IPR&D charge weighed on the P&L. Guidance is the bigger issue: full-year Non-GAAP diluted EPS was cut to $2.80-$3.10 from $4.90-$5.10, with roughly $1.55 of the hit from the Alesta acquisition and $0.32 from the BMN 450 license, while revenue guidance was trimmed to $3,800-$3,900 million on timing of orders from a single international customer. That EPS reset is large enough to force analysts to rebuild models, which is why this matters more than a routine quarterly print.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BMRN was trading at $54.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.1B. The 52-week trading range was $49.26 to $70.98. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.